Chronic Pelvic Pain
and Prostatitis in Men

September 2026 · 9 min read · Clinical Evidence Review

Bottom line: Note that two different technologies are both called "magnetic therapy", and their numbers are not transferable. A 2024 meta-analysis of 8 randomized controlled trials and 636 patients tested functional extracorporeal magnetic innervation (ExMI) — the technology that drives active muscular contraction, not PEMF — and found it reduced the NIH-CPSI symptom index by a mean of 6.65 points (95% CI -8.15 to -5.15, p<0.00001) and improved maximum urinary flow rate by 2.98 mL/s (95% CI 1.36 to 4.59, p=0.0003) — but the improvement in erectile function did not reach significance (IIEF-5, mean difference 0.81, p=0.17) (PubMed 39262719). For proportion: the threshold at which a fall in NIH-CPSI is perceived as a real improvement by the patient is 6 points (PubMed 16468084), so the result clears the threshold but sits right at its lower bound. The measurable target in this indication is pain and urinary symptoms, not a promise about sexual function. The direct evidence for PEMF itself in pelvic pain is far thinner, as set out below.

What Is Chronic Pelvic Pain Syndrome, and Why Does It Reach a Physical Therapy Clinic?

Chronic pelvic pain syndrome is pain in the pelvic region lasting three months or longer, without a proven bacterial infection. In the standard classification it is called CP/CPPS — Chronic Prostatitis / Chronic Pelvic Pain Syndrome — and it is the most common form of "prostatitis" in practice, even though in most cases no organism is ever found. Symptoms fall into three domains: pain (pelvis, perineum, testicles, pain after ejaculation), urinary symptoms (urgency, frequency, weak stream), and quality of life — the three components that make up the standard NIH-CPSI questionnaire.

The reason these patients arrive at a physical clinic is that the pharmacological path has already been exhausted: antibiotics, alpha-blockers and anti-inflammatories were tried and the symptom stayed. That gap — an existing diagnosis with no convincing treatment — is precisely where physical therapy enters, provided it is presented at the right size.

What Did the Largest Meta-Analysis on Magnetic Stimulation Actually Measure?

A 2024 meta-analysis conducted at the Division of Surgery, West China Hospital, Sichuan University, pooled 8 randomized controlled trials and 636 patients and found that extracorporeal magnetic stimulation significantly reduced the NIH-CPSI index. Effect size: a mean reduction of 6.65 points (95% CI -8.15 to -5.15, p<0.00001), alongside an improvement in maximum urinary flow rate (Qmax) of 2.98 mL/s (95% CI 1.36 to 4.59, p=0.0003) versus control (PubMed 39262719).

An independent systematic review from the University of Malaga, Spain — pre-registered in PROSPERO and covering five clinical trials with 278 participants at a mean PEDro score of 7.2 — reached a similar direction on pain, quality of life and urinary symptoms, but stated explicitly that there was no common protocol across the studies (PubMed 35627359). The direction is consistent; the protocol is not.

Are These Numbers Large in Clinical Terms?

Two proportion caveats have to be stated alongside these numbers, or they sound larger than they are. First, the clinical threshold: the validation study of the NIH-CPSI, conducted in 174 men with CP/CPPS within the NIH Chronic Prostatitis Collaborative Research Network, identified on ROC analysis a 6-point decline in the total score as the optimal threshold for predicting treatment response (PubMed 16468084). A 6.65-point reduction does clear that threshold — but by 0.65 of a point, which is a perceptible improvement sitting at the lower bound of the definition, not a step change. Second, urinary flow: an improvement of 2.98 mL/s in Qmax is considered a modest gain in urology, not comparable in magnitude to alpha-blockers or prostate surgery, and it does not guarantee a noticeable change in voiding for every patient. Stating both caveats is not a weakening of the data but expectation-setting, and it is what prevents an argument at the end of the series.

Does Magnetic Treatment Also Improve Sexual Function?

Two studies that examined this directly found no significant improvement — and that is the answer a patient should be given before he asks for it. In the same 636-patient meta-analysis, the IIEF-5 erectile function score showed only a trend: a mean difference of 0.81 points with a confidence interval crossing zero (95% CI -0.34 to 1.95, p=0.17) (PubMed 39262719).

Independently, a prospective interventional trial at Sapienza University of Rome delivered perineal PEMF to 27 men with benign prostatic hyperplasia — five minutes twice daily for 28 days — and found a significant reduction in prostate volume (44.5 to 42.1 mL, p=0.039) and improved urinary symptoms on the IPSS (p=0.045), while reporting explicitly that no changes were found in gonadal hormones or sexual function (PubMed 32090492).

The only trial that measured erection as a primary endpoint is a small double-blind placebo-controlled study from Germany with just 20 participants, in which 80% of the active group reported improved erection intensity and duration versus 30% on placebo (PubMed 12008861). A single trial with 20 participants is not a basis for a clinical promise.

Why Are "Magnetic Stimulation" and PEMF Not the Same Thing?

Most of the evidence in CP/CPPS comes from extracorporeal magnetic stimulation — a technology that produces muscular contraction in the pelvis — and not from low-intensity pulsed electromagnetic fields. The distinction is not semantic: functional magnetic stimulation, such as the pelvic-floor chair, recruits motor neurons and drives active contraction of the pelvic floor muscles, whereas PEMF operates at far lower intensity and targets inflammation, perfusion and tissue repair without producing contraction. The practical consequence is that the effect size from the meta-analysis cannot be transferred one-to-one to PEMF — its eight trials, across 636 patients, tested ExMI only, and not one of them was a PEMF trial.

The only direct PEMF evidence in pelvic pain is a 2022 proof-of-concept case series from Wake Forest School of Medicine: 10 women with bladder pain syndrome were enrolled and 8 completed; 7 of 8 (87.5%) achieved a reduction of 2 points or more in pelvic pain (a 3.0-point drop, p=0.011), but at the 8-week follow-up only 4 of 8 retained the gain, and there was no control group at all (PubMed 35636637). This has to be said plainly: it is an uncontrolled case series — level 4 evidence — in eight women with bladder pain syndrome, not in men with CP/CPPS. The sex differs, the indication differs and the design is weak, so the series appears here as a pointer for future research and not as a basis for an indication.

So When Might PEMF Actually Be Relevant?

When the stated target is the pain and myofascial component of the syndrome, after a urological diagnosis, and not "treatment of the prostate." A substantial share of CP/CPPS patients have a clear musculoskeletal component — trigger points in the pelvic floor, the hip adductors and the abdominal wall — which explains part of the symptom even when the prostate is entirely normal. Three reasonable scenarios for integration:

1. Identified myofascial pain in the pelvis and pelvic girdle, with manual therapy and pelvic floor training continuing together with PEMF — an indication where the PEMF evidence base is broader than it is for the prostate itself. Stated explicitly: this is an extrapolation from a different indication, not direct evidence in CP/CPPS. No trial has tested a PEMF trigger-point protocol in men with chronic prostatitis.
2. A patient who is not a candidate for pharmacological treatment or does not respond to it, where the treatment is presented plainly in advance, and urological follow-up continues as before.
3. A central sensitisation component with stress-related flares — a population that behaves like other chronic pain groups and is managed properly only with a measurable goal defined in advance.

And equally — when not. Suspected active infection, unexamined haematuria, pain appearing for the first time over the age of 50, weight loss, or any urological red flag requires a return to the physician rather than a treatment series. An active electronic implant — pacemaker, implanted defibrillator, neurostimulator or implanted drug pump — is an absolute contraindication to PEMF.

How Does It Compare With the Other Treatments in CP/CPPS?

A 2025 network meta-analysis covering 25 randomized trials and 1,794 patients ranked seven non-pharmacological interventions against each other — and magnetic therapy did not come first. In that analysis, electrical nerve stimulation, shockwave therapy, biofeedback, magnetotherapy and ultrasound were all significantly superior to conventional medication and placebo on the total NIH-CPSI score; however, shockwave therapy ranked above magnetotherapy for pain relief and clinical efficacy, and electrical nerve stimulation led on the total index (PubMed 40787872). And so the table does not hide the competing technology's numbers: a 2026 meta-analysis of 9 randomized trials in men with CP/CPPS and comorbid erectile dysfunction found that shockwave improved erectile function (SMD 0.80, 95% CI 0.31 to 1.28) and reduced NIH-CPSI scores (SMD -1.14, 95% CI -1.73 to -0.55) — at low GRADE certainty for efficacy and high for safety (PubMed 42275556). Those figures appear here in full precisely because they are better than ours in this indication.

A separate study from the Third People's Hospital of Dalian, with 60 men, tested combination rather than competition: sacral nerve root magnetic stimulation added to percutaneous tibial nerve stimulation outperformed tibial stimulation alone (PubMed 36651091). The commercial conclusion runs against intuition: the clinic that presents this ranking as it is — rather than as "the best treatment" — is the one the patient returns to.

Operational Experience Across the PainFree Network

From experience implementing the technology across 70+ Israeli clinics serving a population of 9M — now expanding to the Philippines — the first obstacle in this indication is not clinical but verbal: the patient arrives with the word "inflammation" in his mouth and expects something to eliminate it. Three points recur in the field:

1. Ask what exactly was ruled out, and when. "I had tests" is not information. Urine culture, a PSA test where age-appropriate, and the date of the last urology visit all belong on the intake form, not in conversation.
2. Define the goal as a score, not as a feeling. The NIH-CPSI is short, free and takes two minutes. A clinic that records it at the start and end of a series knows whether it helped; a clinic that does not is arguing with the patient's memory.
3. Say up front that sexual function is not the target. This is the question the patient is thinking about and does not ask. Answered on the therapist's initiative, with the real number, it stops being a credibility test at the end of the series.

These are operational observations from field implementation and are not clinical trial results. The results themselves appear in this article only from the linked sources.

What This Means for Clinic Owners and Investors

This is an audience that searches quietly, stays in long treatment series, and has almost no dedicated physical-therapy address. The value of PEMF here is not in replacing urological follow-up but in extending the clinic's toolkit to patients who arrive after the pharmacological path is exhausted. The system allows hands-free treatment, so the therapist is not tied to the bed for the session, and it integrates alongside manual therapy, pelvic floor training and load management. In the Philippines market, a treatment session in this category is typically priced at ₱1,500–₱2,500. The clinics that succeed in this indication are distinguished not by the device but by the protocol in front of it: a documented urological diagnosis, an implant screen, and a goal defined in advance.